Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Evgen Pharma booked a first-half loss as it continued to develop its portfolio of drug candidates.
Pre-tax losses for the six months through September amounted to £1.61m, compared to losses of £1.79m on-year.
Operational highlights for the year included achieving positive results from a trial of the treatment SFX-01 for metastatic breast cancer, presented at a conference in Barcelona.
Five patients who participated in the STEM trial received SFX-01 treatment for over one year with no tumour progression.
Results from the SFX-01 after a subarachnoid haemorrhage trial, however, did not meet primary or secondary efficacy endpoints.
Cash at 30 September was £5.1m, reflecting an April 2019 fundraise of £5.0m before expenses.
Since the period end the group had received £328k in cash from R&D tax credits.
At 9:53am: (LON:EVG) Evgen Pharma Plc share price was 0p at 7.75p